当前位置: 首页 >> 检索结果
341. Thoracic Aortic Disease in Patients With Heterozygous Variants Outside the Central Region of FBN2.
作者: Till Joscha Demal.;Marco Sachse.;Celia Metzlaff.;Helke Schüler.;Katalin Szöcs.;Jakob Olfe.;Veronika Stark.;Peter Frommolt.;Yskert von Kodolitsch.;Thomas S Mir.;Meike Rybczynski.;Hermann Reichenspurner.;Kerstin Kutsche.;Christian Kubisch.;Christian Detter.;Georg Rosenberger.
来源: Circ Genom Precis Med. 2025年18卷3期e004672页
Heterozygous pathogenic variants in the central region (exon 23-34) of FBN2 cause a hereditary connective tissue disorder named congenital contractural arachnodactyly, which presents with obligatory skeletal features but rarely with vascular manifestations. Scarce data exist on the association between FBN2 variants and aortic disease. This study aimed to investigate whether the location of FBN2 variants correlates with distinct clinical features, including aortic disease.
342. Hemodynamic Right Heart Catheterization Before Transcatheter Mitral and Tricuspid Therapies.
作者: Cosmo Godino.;Antonio Sisinni.;Luca Raone.;Francesco Maria Sparasci.;Andrea Munafò.;Alberto Margonato.;Luca Testa.;Maurizio Taramasso.;Fabien Praz.;Sami Alnasser.;Neil Fam.;Rodrigo Estevez-Loureiro.;Francesco Saia.;Francesco Bedogni.;Azeem Latib.;Claudia Baratto.;Francesca Coppi.;Marianna Adamo.;Altin Palloshi.;Gabriele Crimi.;Scott Lim.;Francesco Maisano.;Ryan J Tedford.;Sergio Caravita.
来源: Circ Heart Fail. 2025年e012489页
Recent findings emphasize the potential role of invasive hemodynamic assessment in guiding transcatheter mitral and tricuspid valve percutaneous interventions. Right heart catheterization-derived parameters offer insights into hemodynamic changes associated with valvular heart diseases, pulmonary hypertension phenotyping, and right ventricular to pulmonary artery coupling. This might improve prognostic stratification for candidates to transcatheter therapies. This review provides a clinical overview of available data regarding the utility of preoperative right heart catheterization-derived parameters in patients undergoing mitral and tricuspid percutaneous repair or replacement.
343. Proteomic Signatures for Risk Prediction of Atrial Fibrillation.
作者: Hanjin Park.;Faye L Norby.;Daehoon Kim.;Eunsun Jang.;Hee Tae Yu.;Tae-Hoon Kim.;Jae-Sun Uhm.;Jung-Hoon Sung.;Hui-Nam Pak.;Moon-Hyoung Lee.;Pil-Sung Yang.;Boyoung Joung.
来源: Circulation. 2025年152卷4期217-229页
Proteomic signatures might improve disease prediction and enable targeted disease prevention and management. We explored whether a protein risk score derived from large-scale proteomics data improves risk prediction of atrial fibrillation (AF).
344. Randomized Study Comparing Angiography Guidance With Physiology Guidance After PCI: The EASY-PREDICT Study.
作者: Paola Ulacia Flores.;Tomas Cieza.;Safia Ouarrak.;Andrés Ruhl.;Siddharta Mengi.;Robert De Larochellière.;David Garcia-Labbé.;Jean-Pierre Déry.;Anthony Poulin.;Éric Larose.;Bernard Noël.;Can Manh Nguyen.;Jean-Michel Paradis.;Olivier F Bertrand.
来源: Circ Cardiovasc Interv. 2025年18卷7期e015165页
Physiology assessment of coronary lesion prepercutaneous coronary intervention (PCI) using hyperemic and nonhyperemic pressure ratios is useful to determine if a lesion requires treatment. Whether the physiology after PCI is superior to angiography guidance only is unknown. The study sought to investigate whether post-PCI physiology improves clinical outcomes compared with standard angiographic guidance.
345. Response to Letter Regarding Article, "Patent Foramen Ovale Closure in Patients With and Without Nickel Hypersensitivity: A Randomized Trial".
作者: Anastasios Apostolos.;Stamatios Gregoriou.;Konstantinos Toutouzas.
来源: Circ Cardiovasc Interv. 2025年18卷6期e015514页 346. Intracellular L-PGDS-Derived 15d-PGJ2 Inhibits CaMKII Through Lipoxidation to Alleviate Cardiac Ischemia/Reperfusion Injury.
作者: Qingmei Hu.;Junxia Zhang.;Xile Luo.;Peiyu Hu.;Jiayi Li.;Fan Li.;Zeyuan Wang.;Shuyang Zhang.;Zishan Jiao.;Yitong Liu.;Jiaxin Duanmu.;Li Jin.;Peng Xie.;Wenneng Zhu.;Wen Zheng.;Haibao Shang.;Xinli Hu.;Zhixing Chen.;Rui-Ping Xiao.;Yan Zhang.
来源: Circulation. 2025年152卷1期41-57页
Myocardial ischemia/reperfusion (I/R) injury is a substantial challenge to the management of ischemic heart disease, the leading cause of mortality worldwide. Arachidonic acid (AA) is a prominent polyunsaturated fatty acid in the human body and plays an important role in various physiological and pathological conditions. AA metabolic enzymes determine AA levels; however, currently there is no comprehensive analysis of AA enzymes in cardiac I/R injury.
347. Feasibility of Computed Tomography as a Gatekeeper for Invasive Angiography Before TAVR: A Pragmatic Real-World Experience.
作者: Asa Phichaphop.;Paul Sorajja.;Maurice Enriquez-Sarano.;Miho Fukui.;Atsushi Okada.;Davide Margonato.;Mohammed Abed.;Takahiro Nishihara.;Hideki Koike.;Evan Walser-Kuntz.;John R Lesser.;Victor Y Cheng.;Vinayak N Bapat.;Nadira Hamid.;João L Cavalcante.
来源: Circ Cardiovasc Interv. 2025年18卷8期e015181页
Although pretranscatheter aortic valve replacement-computed tomography angiography (TAVR-CTA) has shown a good correlation with invasive coronary angiography (ICA) for ruling out obstructive coronary artery disease (CAD), its clinical effectiveness and safety as a gatekeeper for ICA pre-transcatheter aortic valve replacement (pre-TAVR) remain unclear. This study aims to determine whether routine TAVR-CTA, without premedication, could safely defer and guide the need for ICA pre-TAVR.
348. Fragmented QRS, Arrhythmic Causes, and Myocardial Fibrosis Burden by Autopsy Among Countywide Sudden Deaths.
作者: Jakrin Kewcharoen.;Kosuke Nakasuka.;James W Salazar.;Andrew J Connolly.;Ellen Moffatt.;Zian H Tseng.
来源: Circ Arrhythm Electrophysiol. 2025年18卷6期e013809页 349. Valve-in-Valve TAVR for Degenerated Surgical Valves in Patients With Small Aortic Annuli: A Report From a Japanese Nationwide Registry.
作者: Yusuke Oba.;Hiraku Kumamaru.;Satoshi Hoshide.;Shun Kohsaka.;Kazuo Shimamura.;Yohei Ohno.;Masafumi Sato.;Hisaya Kobayashi.;Hiroshi Funayama.;Kenji Harada.;Koji Kawahito.;Kazuomi Kario.
来源: Circ Cardiovasc Interv. 2025年18卷7期e015087页
Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) provides an alternative treatment for high-risk patients with failed surgical bioprosthetic aortic valves. However, limited data exist on ViV-TAVR outcomes in patients with small aortic annuli, particularly among the relatively small-statured Japanese population.
350. Correction to: Target Lesion Revascularization After Intravascular Ultrasound-Guided Percutaneous Coronary Intervention.
作者: Ko Yamamoto.;Hiroki Shiomi.;Takeshi Morimoto.;Akiyoshi Miyazawa.;Hiroki Watanabe.;Masahiro Natsuaki.;Hirotoshi Watanabe.;Kyohei Yamaji.;Masanobu Ohya.;Sunao Nakamura.;Satoru Mitomo.;Satoru Suwa.;Takenori Domei.;Shojiro Tatsushima.;Koh Ono.;Hiroki Sakamoto.;Kiyotaka Shimamura.;Masataka Shigetoshi.;Ryoji Taniguchi.;Yuji Nishimoto.;Hideki Okayama.;Kensho Matsuda.;Takafumi Yokomatsu.;Masahiro Muto.;Ren Kawaguchi.;Koichi Kishi.;Mitsuyoshi Hadase.;Tsutomu Fujita.;Yasunori Nishida.;Masami Nishino.;Hiromasa Otake.;Nobuhiro Suematsu.;Tsuneki Ajimi.;Kengo Tanabe.;Mitsuru Abe.;Kiyoshi Hibi.;Kazushige Kadota.;Kenji Ando.;Takeshi Kimura.; .
来源: Circ Cardiovasc Interv. 2025年18卷5期e000097页 351. Antecedent Flu-Like Illness and Onset of Idiopathic Dilated Cardiomyopathy: The DCM Precision Medicine Study.
作者: Hanyu Ni.;Jinwen Cao.;Daniel D Kinnamon.;Elizabeth Jordan.;Garrie J Haas.;Mark Hofmeyer.;Evan P Kransdorf.;Jamie Diamond.;Anjali Owens.;Brian Lowes.;Douglas Stoller.;W H Wilson Tang.;Mark H Drazner.;Palak Shah.;Jane E Wilcox.;Stuart D Katz.;Javier Jimenez.;Supriya Shore.;Daniel P Judge.;Jonathan O Mead.;Jason Cowan.;Patricia K Parker.;Gordon S Huggins.;Ray E Hershberger.
来源: Circ Heart Fail. 2025年18卷5期e012602页
Previous studies have speculated that a viral infection may act as a trigger in the development of idiopathic dilated cardiomyopathy (DCM) among individuals genetically at risk. This study aims to describe the frequency of patients with DCM who reported experiencing symptoms of flu-like illness before their DCM diagnosis and to examine if this experience modified the association between genetics and DCM.
352. Marshall-Plan Ablation Strategy Versus Pulmonary Vein Isolation in Persistent AF: A Randomized Controlled Trial.
作者: Nicolas Derval.;Romain Tixier.;Josselin Duchateau.;Xavier Bouteiller.;Timothé Loock.;Arnaud Denis.;Rémi Chauvel.;Benjamin Bouyer.;Marine Arnaud.;Masaaki Yokoyama.;Christopher Kowalewski.;Cinzia Monaco.;Ciro Ascione.;Frédéric Sacher.;Mélèze Hocini.;Pierre Jaïs.;Michel Haïssaguerre.;Thomas Pambrun.
来源: Circ Arrhythm Electrophysiol. 2025年18卷5期e013427页
Beyond pulmonary vein (PV) isolation, the optimal ablation strategy for persistent atrial fibrillation (AF) remains poorly defined. The purpose of this study was to compare 2 ablation strategies in the treatment of patients with persistent AF: a comprehensive ablation strategy based on anatomic considerations versus PV isolation alone.
353. Between the Sheets: A Rare Case of HeartMate 3 Pump Failure Due to Electrostatic Interference.
作者: Boaz Elad.;Ersilia M DeFilippis.;Edward Lin.;Jennifer Haythe.;Vivian Feldman.;Ilan Richter.;Melana Yuzefpolskaya.;Paolo C Colombo.;Koji Takeda.;Yuji Kaku.;Gabriel Sayer.;Nir Uriel.;Dor Lotan.
来源: Circ Heart Fail. 2025年18卷8期e012750页 354. Heterogeneous Dysregulation of Myosin Super-Relaxation and Energetics in Hypertrophic Cardiomyopathy.
作者: Julien Ochala.;Miao Feng.;Qian Wang.;Chahida Chaami.;Edgar Nollet.;Christopher T A Lewis.;Anthony L Hessel.;Michelle Michels.;Kenneth C Bedi.;Kenneth B Margulies.;Jose R Pinto.;Kenneth S Campbell.;Diederik W D Kuster.;Jolanda van der Velden.
来源: Circ Heart Fail. 2025年e012614页
Hypertrophic cardiomyopathy is often linked to likely pathogenic and pathogenic variants in genes encoding myofilament proteins. The exact molecular mechanisms by which these lead to cardiac dysfunction and metabolic remodeling remain incompletely understood. Hence, here, we sought to determine whether likely pathogenic and pathogenic variants in thick (MYL2) and thin (TNNI3 or TNNT2) filament genes modulate the myosin super-relaxed state, a critical molecular regulator of heart energetics.
355. Coronary Atherosclerosis Phenotypes in Non-Flow-Limiting Nonculprit Lesions of Older Patients With MI Stratified by Focal and Diffuse Disease Patterns.
作者: Antonella Scala.;Andrea Erriquez.;Marta Cocco.;Filippo Maria Verardi.;Serena Caglioni.;Federico Marchini.;Vincenzo Guiducci.;Gianni Casella.;Marco Ruozzi.;Manfredi Arioti.;Graziella Pompei.;Andrea Picchi.;Iginio Colaiori.;Matteo Serenelli.;Gianluca Campo.;Simone Biscaglia.
来源: Circ Cardiovasc Interv. 2025年18卷7期e015281页 356. 10-Year Outcomes of Deferred or Conventional Stent Implantation in Patients With STEMI (DANAMI-3-DEFER).
作者: Jasmine Melissa Marquard.;Thomas Engstrøm.;Henning Kelbæk.;Rasmus Paulin Beske.;Utsho Islam.;Dan Eik Høfsten.;Lene Holmvang.;Frants Pedersen.;Christian Juhl Terkelsen.;Evald Høj Christiansen.;Hans-Henrik Tilsted.;Charlotte Glinge.;Reza Jabbari.;Ashkan Eftekhari.;Bent Raungaard.;Peter Clemmensen.;Hans Erik Bøtker.;Lisette Okkels Jensen.;Lars Køber.;Jacob Thomsen Lønborg.
来源: Circ Cardiovasc Interv. 2025年18卷6期e015369页
Primary percutaneous coronary intervention (PCI) with stenting is recommended in ST-segment-elevation myocardial infarction. Immediate stenting may cause distal embolization, microvascular damage, and flow disturbances, leading to adverse outcomes. We report the 10-year clinical outcomes of deferred stenting versus conventional PCI in patients with ST-segment-elevation myocardial infarction.
357. Long-Term Safety and Efficacy of Renal Denervation: 24-Month Results From the SPYRAL HTN-ON MED Trial.
作者: David E Kandzari.;Felix Mahfoud.;Raymond R Townsend.;Kazuomi Kario.;Michael A Weber.;Roland E Schmieder.;Konstantinos Tsioufis.;Stuart Pocock.;Minglei Liu.;Vanessa DeBruin.;Sandeep Brar.;Michael Böhm.
来源: Circ Cardiovasc Interv. 2025年18卷7期e015194页
Six-month results from the SPYRAL HTN-ON MED trial (SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral Multi-Electrode Renal Denervation System) demonstrated that renal denervation (RDN) reduced office blood pressure (BP), and not 24-hour ambulatory systolic BP, compared with sham control in hypertensive patients. In this prespecified analysis of the ON MED trial, long-term changes in BP, antihypertensive drug use, and safety outcomes through 24 months are compared between RDN and sham control groups.
358. Validation of a Novel Risk Prediction Score for Sudden Cardiac Death in the Framingham Heart Study.
作者: Thien Tan Tri Tai Truyen.;Honghuang Lin.;Marco Mathias.;Harpriya Chugh.;Kyndaron Reinier.;Emelia J Benjamin.;Sumeet S Chugh.
来源: Circ Arrhythm Electrophysiol. 2025年18卷6期e013647页
We have previously reported a novel clinical risk score (risk prediction score for shockable sudden cardiac arrest [VFRisk]) for the prediction of shockable sudden cardiac arrest, discovered and validated in 2 US west coast communities. We hypothesized that VFRisk predicts sudden cardiac death (SCD) risk in the geographically distinct FHS (Framingham Heart Study).
359. Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.
作者: Albert Wiegman.;Amy L Peterson.;Robert A Hegele.;Eric Bruckert.;Anja Schweizer.;Anastasia Lesogor.;Yibo Wang.;Joep Defesche.
来源: Circulation. 2025年151卷25期1758-1766页
Homozygous familial hypercholesterolemia (HoFH) is a genetic disease characterized by high levels of low-density lipoprotein cholesterol (LDL-C) present from birth, leading to early-onset and progressive atherosclerotic cardiovascular disease. Early treatment initiation is crucial for cardiovascular risk reduction; however, many patients do not reach LDL-C treatment goals. Inclisiran, a small interfering RNA targeting hepatic PCSK9 (proprotein convertase subtilisin/kexin type 9), is effective and well tolerated in adult patients with hyperlipidemia; however, it has not yet been studied in pediatric patients.
360. STAR Locally Prolongs Effective Refractory Period and Increases Ventricular Tachycardia Cycle Length Without Short-Term Scar Formation or Functional Decline: Insights From a Translational Porcine Model Study.
作者: Brian Zenger.;Timothy W Smith.;Stephanie Hicks.;Sherwin Ng.;Todd Pavek.;Nels Knutson.;Pamela P Samson.;Jie Zheng.;Caleb Berberet.;El-Sayed H Ibrahim.;Vinay Jani.;James Tabor.;Leslie D Wilson.;Samuel D Jordan.;Luke C Marut.;Aryan Kumar.;Sneha Manikandan.;Ali Javaheri.;Carmen Bergom.;Julie K Schwarz.;Patrick M Boyle.;Geoffrey D Hugo.;Phillip S Cuculich.;Cliff Robinson.;Christian Zemlin.;Stacey L Rentschler.
来源: Circ Arrhythm Electrophysiol. 2025年18卷6期e013684页
Stereotactic arrhythmia radiotherapy (STAR) has emerged as a potential therapy for treatment-refractory ventricular tachycardia (VT). However, the mechanisms underlying STAR efficacy, such as scar or other electromechanical changes, are still unclear. The goal of this study was to develop a translational porcine model of ischemic monomorphic VT treated with STAR to examine the physiological changes after a typical clinical STAR treatment.
|